Featured science studies simultaneously published in JACC and presented at AHA 2025 looked at artificial intelligence applied to an electrocardiogram (ECG-AI) for heart failure (HF) risk, treatment of Chagas disease, early aspirin withdrawal in STEMI and non-ST-segment elevation acute coronary syndrome (NSTE-ACS), and safety of the pentaspline pulsed-field ablation (PFA) catheter.
JACC Featured Science: ECG-AI For HF Risk; ANSWER-HF; NEO-MINDSET; MANIFEST-US
Related Articles
Mayo Clinic launches 2 new companies to use patient data and AI to advance early disease detection
FIERCE Healthcare: Mayo Clinic has launched a new initiative to collect and analyze patient data from remote monitoring devices and diagnostic tools and to use artificial intelligence to accelerate diagnoses…April 13, 2021
Trial demonstrates early AI-guided detection of heart disease in routine practice
EurekAlert: Heart disease can take a number of forms, but some types of heart disease, such as asymptomatic low ejection fraction, can be hard to recognize, especially in the early…April 18, 2021
Pfizer partners with healthtech company on AI-powered cardiovascular disease detection
Becker's Hospital Review: Pharmaceutical giant Pfizer has partnered with digital health company Anumana, a company founded in 2021 in collaboration with the Mayo Clinic Platform, to develop an artificial intelligence…December 16, 2022
Anumana earns first full FDA clearance for AI to detect low ejection fraction
Fierce Biotech: Two years after its launch as a joint venture between the Mayo Clinic and Nference to develop artificial intelligence algorithms capable of pulling out new insights from routine…October 05, 2023